These indirect side effects of GLP-1 medications can contribute to more significant oral health issues, including increased decay, enamel erosion and enamel wear
Information extracted from eligible articles that were tracked by the reviewers included data such as article title, authors, journal name, year of publication, article type, data source, clinical setting, patient demographics, prior patient pulmonary or gastric history, patient medications noted, system-based comorbidities, extent of adverse event, diagnostics used, study methods, study of patient outcomes, limitations, and conclusions
The most common cost-control mechanisms in place for GLP-1 drugs for weight loss are: utilization management (54%) eligibility requirements (38%) annual maximum (35%) step therapy (23%)
Disclaimer: Retatrutide is not currently FDA approved and is not yet available by prescription